Page 12 - Imaging Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1 July 2008 - 12:00 An article by David Pearson and Colin Webb. This paper talks about the nature of file format obsolescence and a series of prototype questions designed by the National Library as a benchmark to help assess file format obsolescence. The article was published in the International Journal of Digital Curation, Vol 3, No 1 (2008). Introduction We know that in our information-obsessed world, change is everything. And yet some information is required to live beyond the moment; some information is valued beyond tomorrow’s headlines, and must be managed to be accessible, usable, a...

OSA is proud to honor and celebrate outstanding contributions to science, research, engineering, education, industry and society.

Scenic Labs introduces the LX1: Affordable and accurate bias lighting for the home Share Article LX1, the newest addition to Scenic Labs’ acclaimed MediaLight Bias Lighting lineup, offers breakthrough performance and unprecedented quality in a low-cost package, enhancing any home entertainment display's image and reduces eye strain. LX1 Bias Lighting starts at only $15. The simulated D65 / 6500K ColorGrade chip provides a calibrated white reference that enhances any display's image and reduces eye strain. We know how frustrating it can be to find affordable, high-quality bias lighting but y...

 E-Mail Researchers at Rochester Institute of Technology are exploring ways to use drones and artificial intelligence to help farmers and other users assess how well fields of crops are growing. The National Science Foundation awarded Guoyu Lu, an assistant professor in RIT's Chester F. Carlson Center for Imaging Science, more than $583,000 to spearhead the project. The researchers are aiming to create a cost-effective and accurate 3D reconstruction sensing system that can be equipped on unmanned aerial systems. Current systems make use of heavy and expensive 3D Light Detection and Ranging (...

AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease - Topline results expected in November 2022 News provided by Share this article Share this article BALTIMORE, April 21, 2021 /PRNewswire/ -- AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD). The clinical trial, known as "HOPE4MCI...